U.S. equity markets continued their constructive start to 2026, with broad participation across styles, sectors, and market ...

The results indicate that this methodology applied at the end of 2023 resulted in a strong top ten list in 2024. In a year that the Standard & Poor’s SPIVA (S&P vs. Active) blog reported that more ...

The first trading days of the new year were mixed. The dispersion in sector and factor performance underscores an ongoing ...

Happy Holidays from everyone at ValuEngine! Due to the holidays and vacation schedules this week’s Market Summary and Commentary will be brief and missing the ETF and stock performance tables. All ...

ValuEngine is a subscription-based business intelligence, market and equity analysis firm that provides exclusive, customized research and analysis solutions directly to companies, investors, ...

ValuEngine lowered its rating on Surgery Partners’ shares from a “hold” to a “sell,” according to The Ledger Gazette. 1. Surgery Partners’ shares opened Nov. 24 trading at $8.60 per share. 2. The ...